top of page
Browse by category
Search
FDA grants Breakthrough Therapy designation for Zealand Pharma’s survodutide
The FDA has granted Breakthrough Therapy designation to Zealand Pharma’s survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist...
Dasiglucagon effective in preventing post-gastric bypass hypoglycaemia
Post-op hypoglycaemia - Single mini-doses of dasiglucagon effectively reduced time spent in hypoglycaemia after meals in individuals who...
Browse by tag
bottom of page